Related references
Note: Only part of the references are listed.European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience
Fabrizio Vernieri et al.
HEADACHE (2019)
Identifying and managing refractory migraine: barriers and opportunities?
Linda D'Antona et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Andrew Charles et al.
LANCET (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Migraine: Multiple Processes, Complex Pathophysiology
Rami Burstein et al.
JOURNAL OF NEUROSCIENCE (2015)
Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
Piero Barbanti et al.
HEADACHE (2015)
CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine
Eva Cernuda-Morollon et al.
HEADACHE (2014)
CALCITONIN GENE-RELATED PEPTIDE: A MOLECULAR LINK BETWEEN OBESITY AND MIGRAINE?
Ana Recober et al.
DRUG NEWS & PERSPECTIVES (2010)
Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders
P Sarchielli et al.
CEPHALALGIA (2006)